CAMP4 Therapeutics (NASDAQ:CAMP) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of CAMP4 Therapeutics (NASDAQ:CAMP) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

CAMP has been the topic of a number of other reports. Oppenheimer assumed coverage on shares of CAMP4 Therapeutics in a research report on Monday, October 5th. They issued an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Tuesday, September 29th. Needham & Company LLC began coverage on shares of CAMP4 Therapeutics in a research note on Thursday, October 15th. They issued a “buy” rating and a $8.00 price objective for the company. Raymond James Financial initiated coverage on CAMP4 Therapeutics in a report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 price objective on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $10.44.

CAMP4 Therapeutics Stock Up 9.1%

Shares of CAMP4 Therapeutics stock opened at $4.06 on Friday. The firm has a market capitalization of $254.76 million, a P/E ratio of -1.90 and a beta of 0.28. CAMP4 Therapeutics has a 52 week low of $2.90 and a 52 week high of $7.75. The firm’s 50 day moving average is $3.84 and its two-hundred day moving average is $4.20.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.17). The company had revenue of $1.90 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 324.82% and a negative net margin of 2,276.33%. As a group, research analysts expect that CAMP4 Therapeutics will post -0.68 earnings per share for the current fiscal year.

Insider Activity at CAMP4 Therapeutics

In other news, Director Andrew J. Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kelly Gold purchased 10,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the transaction, the chief financial officer owned 10,000 shares in the company, valued at $39,600. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 593,613 shares of company stock valued at $2,504,037 over the last three months. Corporate insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CAMP. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $78,000. Deutsche Bank AG purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $138,000. Bank of New York Mellon Corp purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $365,000. SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 1st quarter worth approximately $1,497,000. Finally, BlackRock Inc. acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $7,185,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.